Predicting Elevated Postvoid Residual Urine Volume Following OnabotulinumtoxinA Treatment for Overactive Bladder: A...

Area of Science:

• Urology
• Pharmacology

Background:

• Idiopathic overactive bladder (OAB) significantly impacts quality of life, with treatments like onabotulinumtoxinA offering relief.
• Elevated postvoid residual volume (PVR) is a potential complication of onabotulinumtoxinA therapy, necessitating identification of predictive factors.

Purpose of the Study:

• To identify predictors of elevated PVR following onabotulinumtoxinA administration in patients with idiopathic OAB.
• To assess the association of patient age and baseline PVR with the likelihood of developing elevated PVR post-treatment.

Main Methods:

• Retrospective review of medical charts from 211 adult patients treated with onabotulinumtoxinA for OAB.
• Logistic regression analysis to evaluate pretreatment urine flow parameters (Qmax, Qavg, Modified Liverpool Qmax/Qavg FI) and baseline PVR as predictors of posttreatment PVR ≥ 200 mL.

Main Results:

• Neither Qmax nor Qavg alone predicted elevated PVR.
• Modified Liverpool Qmax FI (OR 0.30) and Qavg FI (OR 0.07) were significant predictors.
• Increased age and higher baseline PVR were also identified as likely predictors of elevated posttreatment PVR.

Conclusions:

• Older patients with higher baseline PVR and lower pretreatment urine flow indexes face a greater risk of elevated PVR after onabotulinumtoxinA for OAB.
• These findings can inform clinical decision-making regarding patient selection and monitoring for onabotulinumtoxinA therapy.